Amarna's next-generation viral vector platform promises to transform treatment across many disease areas

Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVec  viral gene delivery vector platform, the key to the success of next stage gene and immune-therapies. SVec  is safe, highly efficient, non-immunogenic and vector particles can be produced cost effectively in our SuperVero packaging cell line.

Because of its safety, efficacy and non-immunogenicity in humans our SVec  platform has highly promising qualities for treating the major diseases of our time, creating opportunities to serve the major pharmaceutical markets.

Latest News

Jun 3, 2021
Amarna Therapeutics featured in Biotech NEWS & Life Sciences (Dutch)